A government’s interest in saving lives is not what comes to mind, especially in the ‘rainbow nation’ of South Africa where life expectancy for Black is abysmal and even worse for ethnic-Europeans.

But, South Africa halted the rollout of the AstraZeneca vaccine following a disappointing study indicating that the vaccine is only 22 percent effective against mild and moderate cases of the local variant of the virus.

Undeterred by facts, the Australian regime, whose legislators have fallen over themselves to invest in Covid-related ‘cures’, has now rushed to reassure citizens about the safety and efficacy of the Oxford/AstraZeneca vaccine. This despite a preliminary study in South Africa showed poor results against a local strain.

Since the study was performed on 2,000 mostly young and healthy volunteers who are less likely to develop debilitating symptoms, the effectiveness is unclear, while the overall results are preliminary, the ‘we haven’t got a f****** clue’ stage. .

Nevertheless, the news disturbed many people in Australia, which has secured 53.8 million doses of the AstraZeneca vaccine. Imagine the profits. Australian Health Minister Greg Hunt went on national TV to reassure the public there was no reason to worry. 

‘There is currently no evidence to indicate a reduction in the effectiveness of either the AstraZeneca or Pfizer vaccines in preventing severe disease and death. That is the fundamental task, to protect the health,’ Hunt lied to the on-message state media’s pen-scribblers.

The Australian regime expects 3.8 million doses of the expensive vaccine to arrive in early 2021. The country approved the use of the Pfizer/BioNTech vaccine last month. According to Reuters, is expected to approve the AstraZeneca vaccine within days, ‘or suffer the wrath of the globalist lobby’.

South Africa will continue to offer the Pfizer and Johnson & Johnson vaccines until scientists figure out the best way to deploy the AstraZeneca vaccine, Health Minister Zweli Mkhize said earlier.

The study by the University of the Witwatersrand, Johannesburg, yet to be reviewed, found that the vaccine made by AstraZeneca provides only minimal protection against mild and medium symptoms caused by the B.1.351 coronavirus variant, which was discovered in South Africa in November. The researchers used data from around 2,000 volunteers whose median age was 31.

In a statement to the media, AstraZeneca claimed that the vaccine could protect against severe cases of Covid-19, particularly when the ‘dosing interval is optimized to 8-12 weeks.’ The company was quoted by the Financial Times as saying that it cannot ’properly ascertain’ the effects of the vaccine in the South African study because the participants were young, healthy adults. Source VIDEO